[Comment] Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer

Pancreatic ductal adenocarcinoma, the most common malignancy of the pancreas, remains a lethal disease. Despite substantial recent advancements in systemic therapy, median overall survival in de novo metastatic pancreatic ductal adenocarcinoma is still less than 1 year. FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and gemcitabine plus nab-paclitaxel have been the standard first-line regimens for a decade, with median overall survival of 11·1 months and 8·5 months, respectively, when compared with gemcitabine monotherapy.